Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent

Tina Quanbee Tan; Ram Yogev

doi:10.1586/17512433.1.4.479

Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent

Tina Quanbee Tan, Ram Yogev^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Article

3 Scopus citations

Abstract

The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.

Original language	English (US)
Pages (from-to)	479-489
Number of pages	11
Journal	Expert Review of Clinical Pharmacology
Volume	1
Issue number	4
DOIs	https://doi.org/10.1586/17512433.1.4.479
State	Published - Jul 1 2008

Keywords

Enterococcus
Gram-positive bacteria
Linezolid
Oxazolidinone
Staphydococcus aureus

ASJC Scopus subject areas

Pharmacology, Toxicology and Pharmaceutics(all)
Pharmacology (medical)

Access to Document

10.1586/17512433.1.4.479

Fingerprint Dive into the research topics of 'Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent'. Together they form a unique fingerprint.

Cite this

Tan, T. Q., & Yogev, R. (2008). Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent. Expert Review of Clinical Pharmacology, 1(4), 479-489. https://doi.org/10.1586/17512433.1.4.479

@article{da4186280ac54a7daf40ac923f36beaa,

title = "Clinical pharmacology of linezolid: An oxazolidinone antimicrobial agent",

abstract = "The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.",

keywords = "Enterococcus, Gram-positive bacteria, Linezolid, Oxazolidinone, Staphydococcus aureus",

author = "Tan, {Tina Quanbee} and Ram Yogev",

year = "2008",

month = jul,

day = "1",

doi = "10.1586/17512433.1.4.479",

language = "English (US)",

volume = "1",

pages = "479--489",

journal = "Expert Review of Clinical Pharmacology",

issn = "1751-2433",

publisher = "Expert Reviews Ltd.",

number = "4",

}

TY - JOUR

T1 - Clinical pharmacology of linezolid

T2 - An oxazolidinone antimicrobial agent

AU - Tan, Tina Quanbee

AU - Yogev, Ram

PY - 2008/7/1

Y1 - 2008/7/1

N2 - The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.

AB - The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections caused by antibiotic-resistant Gram-positive pathogens, such as methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus and vancomycin-resistant Enterococcus, in adults and children.

KW - Enterococcus

KW - Gram-positive bacteria

KW - Linezolid

KW - Oxazolidinone

KW - Staphydococcus aureus

UR - http://www.scopus.com/inward/record.url?scp=49449092607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449092607&partnerID=8YFLogxK

U2 - 10.1586/17512433.1.4.479

DO - 10.1586/17512433.1.4.479

M3 - Article

C2 - 24410550

AN - SCOPUS:49449092607

VL - 1

SP - 479

EP - 489

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

IS - 4

ER -